BIONTECH SE-ADR (BNTX)

US09075V1026 - ADR

92.97  +1.27 (+1.38%)

Premarket: 92.27 -0.7 (-0.75%)

Fundamental Rating

6

BNTX gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 592 industry peers in the Biotechnology industry. BNTX scores excellent points on both the profitability and health parts. This is a solid base for a good stock. BNTX is not valued too expensively and it also shows a decent growth rate.



8

1. Profitability

1.1 Basic Checks

BNTX had positive earnings in the past year.
BNTX had a positive operating cash flow in the past year.
Of the past 5 years BNTX 4 years were profitable.
In multiple years BNTX reported negative operating cash flow during the last 5 years.

1.2 Ratios

BNTX has a Return On Assets of 4.04%. This is amongst the best in the industry. BNTX outperforms 95.75% of its industry peers.
BNTX has a Return On Equity of 4.60%. This is amongst the best in the industry. BNTX outperforms 95.24% of its industry peers.
The Return On Invested Capital of BNTX (3.15%) is better than 95.41% of its industry peers.
BNTX had an Average Return On Invested Capital over the past 3 years of 46.52%. This is significantly above the industry average of 13.58%.
The last Return On Invested Capital (3.15%) for BNTX is well below the 3 year average (46.52%), which needs to be investigated, but indicates that BNTX had better years and this may not be a problem.
Industry RankSector Rank
ROA 4.04%
ROE 4.6%
ROIC 3.15%
ROA(3y)36.53%
ROA(5y)17.56%
ROE(3y)46.06%
ROE(5y)20.59%
ROIC(3y)46.52%
ROIC(5y)N/A

1.3 Margins

BNTX's Profit Margin of 24.36% is amongst the best of the industry. BNTX outperforms 98.47% of its industry peers.
In the last couple of years the Profit Margin of BNTX has grown nicely.
BNTX has a Operating Margin of 22.85%. This is amongst the best in the industry. BNTX outperforms 97.62% of its industry peers.
Looking at the Gross Margin, with a value of 84.29%, BNTX belongs to the top of the industry, outperforming 88.78% of the companies in the same industry.
In the last couple of years the Gross Margin of BNTX has remained more or less at the same level.
Industry RankSector Rank
OM 22.85%
PM (TTM) 24.36%
GM 84.29%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y98.55%
PM growth 5YN/A
GM growth 3Y-1.33%
GM growth 5Y-1.09%

8

2. Health

2.1 Basic Checks

BNTX has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.
BNTX has less shares outstanding than it did 1 year ago.
The number of shares outstanding for BNTX has been increased compared to 5 years ago.
Compared to 1 year ago, BNTX has a worse debt to assets ratio.

2.2 Solvency

BNTX has an Altman-Z score of 6.86. This indicates that BNTX is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of BNTX (6.86) is better than 81.46% of its industry peers.
The Debt to FCF ratio of BNTX is 0.05, which is an excellent value as it means it would take BNTX, only 0.05 years of fcf income to pay off all of its debts.
With an excellent Debt to FCF ratio value of 0.05, BNTX belongs to the best of the industry, outperforming 97.79% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that BNTX is not too dependend on debt financing.
The Debt to Equity ratio of BNTX (0.01) is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.05
Altman-Z 6.86
ROIC/WACC0.47
WACC6.69%

2.3 Liquidity

A Current Ratio of 9.43 indicates that BNTX has no problem at all paying its short term obligations.
The Current ratio of BNTX (9.43) is better than 76.87% of its industry peers.
A Quick Ratio of 9.26 indicates that BNTX has no problem at all paying its short term obligations.
With a decent Quick ratio value of 9.26, BNTX is doing good in the industry, outperforming 76.36% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.43
Quick Ratio 9.26

4

3. Growth

3.1 Past

The earnings per share for BNTX have decreased strongly by -89.63% in the last year.
BNTX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 279.64% yearly.
Looking at the last year, BNTX shows a very negative growth in Revenue. The Revenue has decreased by -77.94% in the last year.
The Revenue has been growing by 97.22% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-89.63%
EPS 3Y279.64%
EPS 5YN/A
EPS growth Q2Q-79.48%
Revenue 1Y (TTM)-77.94%
Revenue growth 3Y99.36%
Revenue growth 5Y97.22%
Revenue growth Q2Q-65.43%

3.2 Future

The Earnings Per Share is expected to grow by 1.62% on average over the next years.
The Revenue is expected to grow by 4.44% on average over the next years.
EPS Next Y-83.36%
EPS Next 2Y-51.67%
EPS Next 3Y-25.52%
EPS Next 5Y1.62%
Revenue Next Year-26.39%
Revenue Next 2Y-13.99%
Revenue Next 3Y-2.29%
Revenue Next 5Y4.44%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.

4

4. Valuation

4.1 Price/Earnings Ratio

Based on the Price/Earnings ratio of 22.46, the valuation of BNTX can be described as rather expensive.
Based on the Price/Earnings ratio, BNTX is valued cheaply inside the industry as 96.60% of the companies are valued more expensively.
BNTX's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 26.42.
BNTX is valuated quite expensively with a Price/Forward Earnings ratio of 134.86.
BNTX's Price/Forward Earnings ratio is rather cheap when compared to the industry. BNTX is cheaper than 93.54% of the companies in the same industry.
BNTX's Price/Forward Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 22.74.
Industry RankSector Rank
PE 22.46
Fwd PE 134.86

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, BNTX is valued cheaper than 99.66% of the companies in the same industry.
Industry RankSector Rank
P/FCF 4.38
EV/EBITDA -0.74

4.3 Compensation for Growth

The excellent profitability rating of BNTX may justify a higher PE ratio.
BNTX's earnings are expected to decrease with -25.52% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-51.67%
EPS Next 3Y-25.52%

0

5. Dividend

5.1 Amount

No dividends for BNTX!.
Industry RankSector Rank
Dividend Yield N/A

BIONTECH SE-ADR

NASDAQ:BNTX (3/27/2024, 8:03:00 PM)

Premarket: 92.27 -0.7 (-0.75%)

92.97

+1.27 (+1.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap22.10B
Analysts
Price Target
Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
Industry RankSector Rank
PE 22.46
Fwd PE 134.86
P/S
P/FCF
P/OCF
P/B
P/tB
EV/EBITDA
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 4.04%
ROE 4.6%
ROCE
ROIC
ROICexc
ROICexgc
OM 22.85%
PM (TTM) 24.36%
GM 84.29%
FCFM
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.17
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF
Debt/EBITDA
Cap/Depr
Cap/Sales
Interest Coverage
Cash Conversion
Profit Quality
Current Ratio 9.43
Quick Ratio 9.26
Altman-Z
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)-89.63%
EPS 3Y279.64%
EPS 5Y
EPS growth Q2Q
EPS Next Y-83.36%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)-77.94%
Revenue growth 3Y99.36%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y